Abstract
Background The cytochrome P450 isoenzyme 3A5 (CYP3A5) has an important role on biotransformation of xenobiotics. CYP3A5 SNPs have been associated with variations on enzyme activity that can modify the metabolism of several drugs. Methods In order to evaluate the influence of CYP3A5 variants on response to lowering-cholesterol drugs, 139 individuals with hypercholesterolemia were selected. After a wash-out period of 4 weeks, individuals were treated with atorvastatin (10 mg/day/4 weeks). Genomic DNA was extracted by a salting-out procedure. CYP3A5⁎3C, CYP3A5⁎6 and CYP3A5⁎1D were analyzed by PCR-RFLP and DNA sequencing. Results >Frequencies of the CYP3A5⁎3C and CYP3A5⁎1D alleles were lower in individuals of African descent ( ⁎3C: 47.8% and ⁎1D: 55.2%) than in non-Africans ( ⁎3C: 84.9% and ⁎1D 84.8%, p < 0.01). Non-Africans carrying ⁎3A allele ( ⁎3C and ⁎1D combined alleles) had lower total and LDL-cholesterol response to atorvastatin than non- ⁎3A allele carriers ( p < 0.05). Conclusion CYP3A5⁎3A allele is associated with reduced cholesterol-lowering response to atorvastatin in non-African individuals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
